Impact of CD14 on Reactive Oxygen Species Production from Human Leukocytes Primed by

Escherichia coli / genetics Humans Leukocytes / metabolism Lipopolysaccharide Receptors / metabolism Lipopolysaccharides / metabolism Oxidative Stress Reactive Oxygen Species

Journal

Oxidative medicine and cellular longevity
ISSN: 1942-0994
Titre abrégé: Oxid Med Cell Longev
Pays: United States
ID NLM: 101479826

Informations de publication

Date de publication:
2019
Historique:
received: 17 12 2018
accepted: 11 02 2019
entrez: 5 4 2019
pubmed: 5 4 2019
medline: 24 4 2019
Statut: epublish

Résumé

Lipopolysaccharides (LPS) from Gram-negative bacteria prime human polymorphonuclear neutrophils (PMNs) via multicomponent receptor cluster including CD14 and MD-2·TLR4 for the enhanced release of reactive oxygen species (ROS) were triggered by bacterial derived peptide

Identifiants

DOI: 10.1155/2019/6043245 PMID: 30944694 PMC: PMC6421816
pubmed: 30944694
doi: 10.1155/2019/6043245
pmc: PMC6421816
doi:

Substances chimiques

Lipopolysaccharide Receptors 0
Lipopolysaccharides 0
Reactive Oxygen Species 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

6043245

Références

J Clin Invest. 1999 Mar;103(6):851-8
pubmed: 10079106
J Biol Chem. 2000 Nov 24;275(47):36713-9
pubmed: 10976103
J Immunol. 2000 Nov 15;165(10):5780-7
pubmed: 11067937
J Immunol. 2001 Mar 1;166(5):3599-605
pubmed: 11207321
Cell Signal. 2001 May;13(5):335-43
pubmed: 11369515
Biochemistry (Mosc). 2001 Aug;66(8):840-9
pubmed: 11566053
Infect Immun. 2002 Aug;70(8):4068-74
pubmed: 12117913
Curr Opin Lipidol. 2002 Oct;13(5):513-21
pubmed: 12352015
J Clin Microbiol. 2002 Nov;40(11):4372-4
pubmed: 12409435
Circulation. 2002 Dec 3;106(23):2894-900
pubmed: 12460868
J Clin Immunol. 2003 Mar;23(2):132-40
pubmed: 12757265
Infect Immun. 1992 Mar;60(3):845-52
pubmed: 1371770
Biochem Biophys Res Commun. 1992 Mar 31;183(3):1280-6
pubmed: 1373609
Hybrid Hybridomics. 2003 Dec;22(6):357-65
pubmed: 14683595
Cardiovasc Res. 2004 Feb 15;61(3):481-97
pubmed: 14962479
Int Immunopharmacol. 2004 Mar;4(3):327-47
pubmed: 15037211
J Immunol. 2004 May 15;172(10):6185-94
pubmed: 15128806
Am J Cardiol. 2005 Jun 6;95(11A):3C-8C; discussion 38C-40C
pubmed: 15925558
Cardiovasc Pathol. 2005 Sep-Oct;14(5):247-50
pubmed: 16168897
Annu Rev Immunol. 2006;24:353-89
pubmed: 16551253
Cell Microbiol. 2006 Dec;8(12):1899-909
pubmed: 16848791
Science. 1990 Sep 21;249(4975):1431-3
pubmed: 1698311
Free Radic Biol Med. 2007 Jan 15;42(2):153-64
pubmed: 17189821
J Immunol. 2007 Jun 1;178(11):7344-56
pubmed: 17513785
Biochem Pharmacol. 2007 Aug 1;74(3):457-64
pubmed: 17544376
Nat Rev Immunol. 2008 Jan;8(1):34-47
pubmed: 18064051
J Leukoc Biol. 2008 Jul;84(1):280-91
pubmed: 18458151
Eur Respir J. 2009 Jun;33(6):1467-84
pubmed: 19483049
PLoS Pathog. 2009 Jun;5(6):e1000464
pubmed: 19503602
J Mol Cell Cardiol. 2010 Jun;48(6):1236-44
pubmed: 20211628
Biochemistry (Mosc). 2010 Apr;75(4):383-404
pubmed: 20618127
Nat Immunol. 2010 Aug;11(8):691-3
pubmed: 20644576
Cell Mol Life Sci. 2010 Dec;67(24):4109-34
pubmed: 20680392
Oxid Med Cell Longev. 2010 May-Jun;3(3):214-8
pubmed: 20716946
J Immunol. 1990 Nov 1;145(9):3017-25
pubmed: 2170529
Adv Exp Med Biol. 2012;946:237-51
pubmed: 21948372
Biochemistry (Mosc). 2013 Feb;78(2):185-93
pubmed: 23581989
Int Immunopharmacol. 2013 Nov;17(3):638-50
pubmed: 23994464
Can J Microbiol. 2013 Oct;59(10):645-55
pubmed: 24102217
Mol Immunol. 2014 Feb;57(2):210-5
pubmed: 24172224
Clin Invest Med. 2014 Apr 01;37(2):E58-69
pubmed: 24690420
Biochemistry (Mosc). 2014 Aug;79(8):812-9
pubmed: 25365491
Mol Cell Biochem. 2017 Sep;433(1-2):177-194
pubmed: 28386844
Pharmacol Ther. 2018 Jan;181:169-182
pubmed: 28842273
Front Cell Infect Microbiol. 2017 Aug 25;7:373
pubmed: 28890882
Am J Pathol. 1985 Apr;119(1):101-10
pubmed: 2984939
Oxid Med Cell Longev. 2018 Jul 19;2018:5979721
pubmed: 30116485
Oxid Med Cell Longev. 2018 Aug 2;2018:9390140
pubmed: 30174784
Clin Cosmet Investig Dermatol. 2018 Oct 24;11:515-520
pubmed: 30425546
Eur J Biochem. 1969 Jun;9(2):245-9
pubmed: 5804498
Infect Immun. 1994 Mar;62(3):922-7
pubmed: 7509321
Infect Immun. 1995 Jan;63(1):248-52
pubmed: 7528732
J Leukoc Biol. 1995 Mar;57(3):440-9
pubmed: 7533819
J Biol Chem. 1995 Jul 21;270(29):17237-42
pubmed: 7542233
J Immunol. 1993 Mar 1;150(5):1988-97
pubmed: 7679700
Crit Care Med. 1996 Mar;24(3):392-7
pubmed: 8625625
J Leukoc Biol. 1997 Feb;61(2):173-8
pubmed: 9021923
Eur J Biochem. 1997 Jan 15;243(1-2):100-9
pubmed: 9030727
Anal Biochem. 1976 May 7;72:248-54
pubmed: 942051
J Clin Invest. 1998 Dec 1;102(11):2019-27
pubmed: 9835628
J Biol Chem. 1999 Jan 1;274(1):537-42
pubmed: 9867877
Anal Biochem. 1999 Feb 1;267(1):161-8
pubmed: 9918668

Auteurs

Dmitry S Kabanov (DS)

Department of Molecular Biomedicine, Federal Research Center "Pushchino Scientific Center for Biological Research of the Russian Academy of Sciences", Pushchino 142290, Russia.
ORCID: 0000-0001-8263-3079

Olga Yu Vwedenskaya (OY)

Department of Pathology of the Institute of Pharmacy, SBAE I. M. Sechenov's First Moscow State Medical University of Russian Healthcare Ministry, Moscow 119811, Russia.

Marina A Fokina (MA)

Department of Pathology of the Institute of Pharmacy, SBAE I. M. Sechenov's First Moscow State Medical University of Russian Healthcare Ministry, Moscow 119811, Russia.

Elena M Morozova (EM)

Department of Pathology of the Institute of Pharmacy, SBAE I. M. Sechenov's First Moscow State Medical University of Russian Healthcare Ministry, Moscow 119811, Russia.

Sergey V Grachev (SV)

Department of Molecular Biomedicine, Federal Research Center "Pushchino Scientific Center for Biological Research of the Russian Academy of Sciences", Pushchino 142290, Russia.
Department of Pathology of the Institute of Pharmacy, SBAE I. M. Sechenov's First Moscow State Medical University of Russian Healthcare Ministry, Moscow 119811, Russia.

Isabella R Prokhorenko (IR)

Department of Molecular Biomedicine, Federal Research Center "Pushchino Scientific Center for Biological Research of the Russian Academy of Sciences", Pushchino 142290, Russia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Bactéries › Proteobacteria › Gammaproteobacteria › Enterobacteriaceae › Escherichia › Escherichia coli › Impact of CD14 on Reactive Oxygen Species...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Impact of CD14 on Reactive Oxygen Species...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Impact of CD14 on Reactive Oxygen Species...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Antigènes de différenciation › Antigènes de différenciation des myélomonocytes › Antigènes CD14 › Impact of CD14 on Reactive Oxygen Species...
questionsmedicales.fr › Facteurs biologiques › Toxines biologiques › Toxines bactériennes › Endotoxines › Lipopolysaccharides › Impact of CD14 on Reactive Oxygen Species...
questionsmedicales.fr › Phénomènes physiologiques › Stress physiologique › Stress oxydatif › Impact of CD14 on Reactive Oxygen Species...
questionsmedicales.fr › Produits chimiques inorganiques › Composés de l'oxygène › Espèces réactives de l'oxygène › Impact of CD14 on Reactive Oxygen Species...